CLARATYNE

Main information

  • Trade name:
  • CLARATYNE REDITABS loratadine 10mg orally disintegrating tablet blister pack
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • CLARATYNE REDITABS loratadine 10mg orally disintegrating tablet blister pack
    Australia
  • Language:
  • English

Other information

Status

  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 217147
  • Last update:
  • 09-10-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:

217147

CLARATYNE REDITABS loratadine 10mg orally disintegrating tablet blister pack

ARTG entry for

Medicine Registered

Sponsor

Bayer Australia Ltd

Postal Address

PO Box 182,Gordon NSW 2072,Gordon, NSW, 2072

Australia

ARTG Start Date

12/11/2013

Product category

Medicine

Status

Active

Approval area

Non-Prescription Medicines

Conditions

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods

Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered

or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Products

1. CLARATYNE REDITABS loratadine 10mg orally disintegrating tablet blister pack

Product Type

Single Medicine Product

Effective date

15/06/2017

Warnings

No Warnings included on Record

Standard Indications

Specific Indications

For use in the treatment of both seasonal & perennial allergic rhinitis in adults & children 12 years of age or older. Also indicated for the relief of

symptoms & signs of chronic urticaria in adults & children 12 years & older.

Additional Product information

Container information

Type

Material

Life Time

Temperature

Closure

Conditions

Blister Pack

Al/Al

3 Years

Store below 25

degrees Celsius

Not recorded

Not recorded

Pack Size/Poison information

Pack Size

Poison Schedule

(S2) Pharmacy Medicine

30's

(S2) Pharmacy Medicine

10's

(S2) Pharmacy Medicine

50's

(S2) Pharmacy Medicine

75's

(S2) Pharmacy Medicine

60's

(S2) Pharmacy Medicine

(S2) Pharmacy Medicine

20's

(S2) Pharmacy Medicine

Components

1.

Dosage Form

Tablet, orally disintegrating

Route of Administration

Oral

Visual Identification

white, round, tablet-shaped units debossed with 'C10'.

Active Ingredients

Loratadine

10 mg

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 1 of

Produced at 19.10.2017 at 11:19:02 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

3-7-2018

Aerius (Merck Sharp and Dohme B.V.)

Aerius (Merck Sharp and Dohme B.V.)

Aerius (Active substance: desloratadine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4255 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/313/T/90

Europe -DG Health and Food Safety

3-7-2018

Azomyr (Merck Sharp and Dohme B.V.)

Azomyr (Merck Sharp and Dohme B.V.)

Azomyr (Active substance: desloratadine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4253 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/310/T/94

Europe -DG Health and Food Safety

19-6-2018

Aerinaze (Merck Sharp and Dohme Limited)

Aerinaze (Merck Sharp and Dohme Limited)

Aerinaze (Active substance: desloratadine; pseudoephedrine sulphate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3930 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/772/T/37

Europe -DG Health and Food Safety

19-6-2018

Neoclarityn (Merck Sharp and Dohme Limited)

Neoclarityn (Merck Sharp and Dohme Limited)

Neoclarityn (Active substance: desloratadine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3931 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/314/T/88

Europe -DG Health and Food Safety